New Search

Your search found 11 records, sorted newest to oldest.

1. Craving Intensity and Withdrawal Severity Across Phases of Opioid Detoxification with Buprenorphine. doc type
  Chen, Hanhui ; Hillhouse, Maureen ; Doraimani, Geetha ; Hasson, Albert ; Ling, Walter
  Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, Scottsdale, AZ, June 12-17, 2010.
 
2. Association of Race and Ethnicity with Withdrawal Symptoms, Attrition, Opioid Use, and Side-Effects During Buprenorphine Therapy. doc type
  Brown, E. Sherwood ; Tirado, Carlos F. ; Minhajuddin, Abu T. ; Hillhouse, Maureen ; Adinoff, Bryon H. ; Ling, Walter ; Doraimani, Geetha ; Thomas, Christie
  Journal of Ethnicity in Substance Abuse 2010;9(2):106-114. [doi: 10.1080/15332641003772587].
 
3. Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment on Smoking Cessation Intervention in ADHD Smokers: A Randomized, Double-Blind, Placebo-Controlled Trial. doc type doc type
  Winhusen, Theresa M. ; Somoza, Eugene C. ; Brigham, Gregory S. ; Liu, David S. ; Green, Carla A. ; Covey, Lirio S. ; Croghan, Ivana T. ; Adler, Lenard A. ; Weiss, Roger D. ; Leimberger, Jeffrey D. ; Lewis, Daniel F. ; Dorer, Emily M.
  Journal of Clinical Psychiatry 2010 (in press). [doi: 10.4088/JCP.09m05089gry].
 
4. OROS-Methylphenidate or Placebo for Adult Smokers with Attention Deficit Hyperactivity Disorder: Racial/Ethnic Differences. doc type
  Covey, Lirio S. ; Hu, Mei-Chen ; Winhusen, Theresa M. ; Weissman, Judith ; Berlin, Ivan ; Nunes, Edward V.
  Poster presented at the NIDA Blending Conference, "Blending Addiction Science and Practice: Evidence-Based Treatment and Prevention in Diverse Populations and Settings," Albuquerque, NM, April 22-23, 2010.
 
5. OROS-Methylphenidate or Placebo for Adult Smokers with Attention Deficit Hyperactivity Disorder: Racial/Ethnic Differences. doc type
  Covey, Lirio S. ; Hu, Mei-Chen ; Winhusen, Theresa M. ; Weissman, Judith ; Berlin, Ivan ; Nunes, Edward V.
  Drug and Alcohol Dependence 2010;110(1-2):156-159. [doi: 10.1016/j.drugalcdep.2010.02.002].
 
6. Gender Differences at Presentation for Treatment-Seeking Opiate Dependence. doc type
  Haynes, Louise F. ; Carter, Rickey E. ; Back, Sudie E. ; Payne, Rebecca ; Hillhouse, Maureen
  Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, Reno/Sparks, Nevada, June 20-25, 2009.
 
7. Buprenorphine Tapering Schedule and Illicit Opioid Use. doc type doc type
  Ling, Walter ; Hillhouse, Maureen ; Domier, Catherine P. ; Doraimani, Geetha ; Hunter, Jeremy ; Thomas, Christie ; Jenkins, Jessica ; Hasson, Albert ; Annon, Jeffrey J. ; Saxon, Andrew J. ; Selzer, Jeffrey A. ; Boverman, Joshua ; Bilangi, Richard
  Addiction 2009;104(2):256-265 [doi: 10.1111/j.1360-0443.2008.02455.x].
 
8. Standardized Patients as Participants in Clinical Trials Protocol Implementation. doc type
  Fussell, Holly E. ; Kunkel, Lynn E. ; Shannon-Lewy, Colleen ; McFarland, Bentson H.
  Poster presented at the NIDA Blending Conference, "Blending Addiction Science & Practice: Bridges to the Future," Seattle, WA, October 16-17, 2006.
 
9. Using Standardized Patients to Pilot Screening Visits in Clinical Trials. doc type
  Kunkel, Lynn E. ; Fussell, Holly E. ; Shannon-Lewy, Colleen ; McFarland, Bentson H.
  Poster presented at the Society for Clinical Trials Annual Meeting, Montreal, Canada, May 20-23, 2007.
 
10. Smoking Cessation Study for Smokers with Attention Deficit Hyperactivity Disorder (ADHD): Should I Participate? doc type
  NIDA Center for the Clinical Trials Network (NIDA CCTN)
 
 
11. Suboxone (Buprenorphine/Naloxone) Taper: A Comparison of Taper Schedules. Should I Join? doc type
  NIDA Center for the Clinical Trials Network (NIDA CCTN)
 
 

New Search

Powered by DB/Text WebPublisher, from Inmagic WebPublisher PRO